Wedbush Reiterates Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

Wedbush reiterated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report issued on Monday, RTT News reports. They currently have a $23.00 target price on the stock. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at ($0.58) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($0.94) EPS.

Several other equities analysts have also recently issued reports on YMAB. Truist Financial assumed coverage on Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a buy rating and a $21.00 target price on the stock. HC Wainwright upped their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a buy rating in a research note on Monday, May 13th. Two equities research analysts have rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $19.29.

Y-mAbs Therapeutics Price Performance

YMAB stock opened at $12.21 on Monday. Y-mAbs Therapeutics has a 12 month low of $4.69 and a 12 month high of $20.90. The company has a market cap of $535.81 million, a price-to-earnings ratio of -24.92 and a beta of 0.66. The company has a fifty day moving average price of $11.84 and a 200 day moving average price of $13.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The company had revenue of $22.80 million for the quarter, compared to analyst estimates of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. During the same period in the previous year, the business posted ($0.14) earnings per share. As a group, analysts anticipate that Y-mAbs Therapeutics will post -0.52 earnings per share for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 35,000 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $12.03, for a total value of $421,050.00. Following the completion of the transaction, the insider now directly owns 197,681 shares of the company’s stock, valued at $2,378,102.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Bo Kruse sold 31,371 shares of the stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the transaction, the chief financial officer now directly owns 210,877 shares in the company, valued at approximately $2,545,285.39. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Thomas Gad sold 35,000 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $12.03, for a total transaction of $421,050.00. Following the transaction, the insider now directly owns 197,681 shares in the company, valued at approximately $2,378,102.43. The disclosure for this sale can be found here. Insiders sold 99,444 shares of company stock valued at $1,203,925 in the last 90 days. 21.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its position in Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after purchasing an additional 65,732 shares during the period. Los Angeles Capital Management LLC increased its stake in Y-mAbs Therapeutics by 17.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock worth $2,432,000 after buying an additional 52,610 shares during the period. Millennium Management LLC lifted its holdings in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after buying an additional 67,233 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Y-mAbs Therapeutics by 143.4% in the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Y-mAbs Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock valued at $1,461,000 after purchasing an additional 8,974 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.